Summary: Sodium-glucose co-transporter type 2 (SGLT2) inhibitors are currently a group of essential drugs for the treatment of type 2 diabetes and chronic kidney disease. In both of these indications they reduce cardiovascular endpoints. Furthermore, SGLT-2 inhibitors have reached an unique position in the treatment of heart failure, as the core agents across the whole left ventricular ejection fraction, irrespectively of the age, gender and comorbidities of patients, as well as the previously administered treatment. This is reflected in the latest guidelines of international scientific societies, including the European Society of Cardiology and the American College of Cardiology. According to them, SGLT2 inhibitors are recommended as the baseline pharmacotherapy in HF to reduce the risk of hospitalization and cardiovascular death. In the group of patient with heart failure with preserved EF (HFpEF) the position of SGLT2 inhibitors is crucial due to the lack of alternative treatment to improve long-term prognosis. Such indications have been currently confirmed for two analogues of SGLT2 inhibitors: dapagliflozin and empagliflozin. The profound analysis of the results of current clinical trials shows that, irrespectively of EF, only dapagliflozin reached a statistically significant effect on the reduction of cardiovascular, and total mortality in chronic HF.